Sipuleucel-T: Harbinger of a new age of therapeutics for prostate cancer

Expert Review of Vaccines

Volumn 10, Issue 2, 2011, Pages 141-150

  Madan, Ravi A ^a   Gulley, James L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cancer treatment; cancer vaccine; immunotherapy; prostate cancer

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ANDROGEN; ANDROGEN RECEPTOR; BEVACIZUMAB; CABAZITAXEL; CANCER VACCINE; CYTOCHROME P450 17; CYTOCHROME P450 17A; DOCETAXEL; GAMMA INTERFERON; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROSTVAC; PROVENGE; PSA TRICOM; UNCLASSIFIED DRUG;

ANDROGEN SYNTHESIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CHILL; CYTOKINE PRODUCTION; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; GLEASON SCORE; HUMAN; LIFE EXPECTANCY; LYMPHOCYTE PROLIFERATION; MAXIMUM TOLERATED DOSE; MYALGIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; T LYMPHOCYTE; TUMOR IMMUNITY; VACCINE PRODUCTION;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; MALE; PROSTATIC NEOPLASMS; TISSUE EXTRACTS; UNITED STATES;

EID: 79951871014     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.173     Document Type: Article

References (81)

1. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 210(4), 474-484; discussion 484-475 (1989)
2. Holdener EE, Emmons RP, Brunda M, Evans L, Levitt D. Interferon-a and interleukin-2 in the treatment of renal cell cancer. Prog. Clin. Biol. Res. 348, 61-69 (1990)
3. Ressing ME, Offringa R, Toes RE, et al. Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity. Immunotechnology 2(4), 241-251 (1996) (Pubitemid 27037858)
4. Chakraborty NG, Stevens RL, Mehrotra S, et al. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol. Immunother. 52(8), 497-505 (2003) (Pubitemid 36963211)
5. Coffey DS, Isaacs JT. Prostate tumor biology and cell kinetics - theory. Urology 17(Suppl. 3), 40-53 (1981) (Pubitemid 11110414)
6. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 62(15), 4427-4433 (2002) (Pubitemid 34827303)
7. Fong L, Small EJ. Immunotherapy for prostate cancer. Semin. Oncol. 30(5), 649-658 (2003) (Pubitemid 37296789)
8. Cereda V, Poole DJ, Palena C, et al. New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. Cancer Immunol. Immunother. 59(1), 63-71 (2010)
9. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 145(5), 907-923 (1991)
10. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard deflnitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res. 11(9), 3353-3362 (2005) (Pubitemid 40627887)
11. Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J. Clin. lmmunol. 24(5), 571-578 (2000) (Pubitemid 39221675)
12. Burch PA, Breen JK, Buckner JC, et al. Priming tissue-specific cellular immunity in a Phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 6(6), 2175-2182 (2000) (Pubitemid 30399182)
13. So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev. Anticancer Ther. 6(9), 1163-1167 (2006) (Pubitemid 44575570)
14. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362(6422), 755-758 (1993) (Pubitemid 23125980)
15. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 294(2), 238-244 (2005) (Pubitemid 41043794)
16. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18(23), 3894-3903 (2000)
17. Burch PA, Croghan GA, Gastineau DA, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 60(3), 197-204 (2004) (Pubitemid 38971831)
18. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24(19), 3089-3094 (2006) (Pubitemid 46638945)
19. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115(16), 3670-3679 (2009)
20. Small E, Rini B, Higano C, et al. A randomized, placebo-controlled Phase III trial of APC8015 in patients with androgen-independent prostate cancer (AiPCa) [abstract]. Proc. Am. Soc. Clin. Oncol. 22, 1534 (2003)
21. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010)
22. Sheikh N, Jones L. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol. Immunother. 57(9), 1381-1390 (2008)
23. Stewart F, dela Rosa C, Sheikh N, et al. Correlation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer [abstract]. J. Clin. Oncol. 28(15S), 4552 (2010)
24. Frohlich M, Sheikh N, Xu Y, Whitmore J, Poehlein C, Urdal D. Sipuleucel-T immune parameters and correlation with overall survival. Presented at: iSBTC 25th Annual Scientific Meeting. Washington, DC, USA, 30 September-4 October 2010
25. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502-1512 (2004) (Pubitemid 39315317)
26. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513-1520 (2004) (Pubitemid 39315318)
27. Moore MJ, Osoba D, Murphy K, et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J. Clin. Oncol. 12(4), 689-694 (1994) (Pubitemid 24110906)
28. Kelly W, Halabi S, Carducci M, et al. A randomized, double-blind, placebo-controlled Phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401 [abstract]. J. Clin. Oncol. 28(18s), LBA4511 (2010)
29. Huggins C, Bergenstal DM. Inhibition of human mammary and prostatic cancers by adrenalectomy. Cancer Res. 12(2), 134-141 (1952)
30. Furr BJ. Casodex (ICI 176,334) - a new, pure, peripherally-selective anti-androgen: preclinical studies. Horm. Res. 32(Suppl. 1), 69-76 (1989) (Pubitemid 20028548)
31. Madan RA, Arlen PM. Abiraterone. Cougar Biotechnology. IDrugs 9(1), 49-55 (2006)
32. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26(28), 4563-4571 (2008)
33. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27(23), 3742-3748 (2009)
34. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 28(9), 1496-1501 (2010)
35. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928), 787-790 (2009)
36. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a Phase 1-2 study. Lancet 375(9724), 1437-1446 (2010)
37. Sartor A, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational Phase III trial (TROPIC). Presented at: ASCO Genitourinary Cancers Symposium. San Francisco, CA, USA, 5-7 March 2010
38. Halabi S, Vogelzang NJ, Kornblith AB, et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J. Clin. Oncol. 26(15), 2544-2549 (2008)
39. Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother. 59(5), 663-674 (2010)
40. Longo DL. New therapies for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 479-481 (2010)
41. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin. Investig. Drugs 18(7), 1001-1011 (2009)
42. Essajee S, Kaufman HL. Poxvirus vaccines for cancer and HIV therapy. Expert Opin. Biol. Ther. 4(4), 575-588 (2004) (Pubitemid 38480556)
43. Gulley J, Chen AP, Dahut W, et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate 53(2), 109-117 (2002)
44. Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 22(11), 2122-2132 (2004) (Pubitemid 41095145)
45. Arlen PM, Skarupa L, Pazdur M, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J. Urol. 178(4 Pt 1), 1515-1520 (2007) (Pubitemid 47368382)
46. DiPaola R, Chen Y, Bubley G, et al. A Phase II study of PROSTVAC-V (vaccinia)/TRICOM and PROSTVAC-F (fowlpox)/TRICOM with GM-CSF in patients with PSA progression after local therapy for prostate cancer: Results of ECOG 9802. Presented at: ASCO Genitourinary Cancers Symposium. Orlando, FL, USA, 26- 28 February 2009
47. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59(22), 5800-5807 (1999)
48. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res. 62(20), 5770-5777 (2002) (Pubitemid 35204734)
49. Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. 61(11), 4497-4505 (2001) (Pubitemid 32685780)
50. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a Phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28(7), 1099-1105 (2010)
51. Baghdadi R. Dendreon vs CMS: why the Provenge coverage controversy is bigger than just one product. Oncology 24(10), 881-883 (2010)
52. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the 440 billion question. J. Natl Cancer Inst. 101(15), 1044-1048 (2009)
53. Cancer patients receiving chemotherapy: opportunities for better management. Milliman Client Report. Milliman Inc., NY, USA, 1-30 (2010)
54. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010)
55. Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 15(9), 969-975 (2010)
56. Stein WD, Gulley J, Schlom J, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials. The growth rate as an indicator of therapeutic efficacy. Clin. Cancer Res. DOI: 10.1158/1078-0432.CCR- 10-1762 (2010) (Epub ahead of print)
57. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26(7), 1148-1159 (2008)
58. Madan RA, Mohebtash M, Schlom J, Gulley JL. Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Expert Opin. Biol. Ther. 10(1), 19-28 (2010)
59. McNeel DG, Dunphy EJ, Davies JG, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J. Clin. Oncol. 27(25), 4047-4054 (2009)
60. Zlotocha S, Staab MJ, Horvath D, et al. A Phase I study of a DNA vaccine targeting prostatic acid phosphatase in patients with stage D0 prostate cancer. Clin. Genitourin. Cancer 4(3), 215-218 (2005)
61. Arlen PM, Gulley JL, Todd N, et al. Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J. Urol. 174(2), 539-546 (2005) (Pubitemid 40981596)
62. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res. 11(9), 3353-3362 (2005) (Pubitemid 40627887)
63. Arlen PM, Gulley JL, Parker C, et al. A randomized Phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res. 12(4), 1260-1269 (2006) (Pubitemid 43342517)
64. Tseng CW, Trimble C, Zeng Q, et al. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts. Cancer Immunol. Immunother. 58(5), 737-748 (2009)
65. Newcomb EW, Demaria S, Lukyanov Y, et al. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin. Cancer Res. 12(15), 4730-4737 (2006) (Pubitemid 44297827)
66. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 64(21), 7985-7994 (2004) (Pubitemid 39446933)
67. Madan RA, Gulley JL, Schlom J, et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin. Cancer Res. 14(14), 4526-4531 (2008)
68. Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl Acad. Sci. USA 98(25), 14565-14570 (2001) (Pubitemid 33121432)
69. Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci. 12, 4957-4971 (2007)
70. Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7(3), 239-249 (2005) (Pubitemid 40568683)
71. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270(5238), 985-988 (1995)
72. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3(7), 611-618 (2002)
73. Allison JP, Chambers C, Hurwitz A, et al. A role for CTLA-4-mediated inhibitory signals in peripheral T cell tolerance? Novartis Found. Symp. 215, 92-98; discussion 98-102, 186-190 (1998)
74. Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J. Multiple costimulatory modalities enhance CTL avidity. J. Immunol. 174(10), 5994-6004 (2005) (Pubitemid 40663786)
75. Boehm AL, Higgins J, Franzusoff A, Schlom J, Hodge JW. Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunol. Immunother. 59(3), 397-408 (2010)
76. FDA Prescribing Information for Provenge. PROVENGE® Package Insert www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ ApprovedProducts/UCM210031.pdf
77. FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer. FDA Press Release www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm210174.htm
78. Study of Investigational Agent Abiraterone Acetate for Metastatic Advanced Prostate Cancer Unblinded After Meeting Pre-Determined Criteria. Cougar Biotechnology Press Release, 9 September 2010 www.prnewswire.com/news-releases/ study-of-investigational-agent-abiraterone-acetate-for-metastatic-advanced- prostate-cancer-unblinded-after-meeting-pre-determined-criteria-102576469.html
79. Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer. NIH Clinical Trials, updated 21 May 2010 http://clinicaltrials.gov/ct2/show/NCT00887198?term= abiraterone&rank=10
80. Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM). NIH Clinical Trials, updated 22 September 2010 http://clinicaltrials.gov/ct2/show/NCT00974311?term=MDV3100&rank=3
81. Cabazitaxel. FDA Press Release, 17 June 2010 www.fda.gov/AboutFDA/ CentersOffices/CDER/ucm216214.htm